Burkitt Lymphoma in Elderly Patients

Abstract

SUMMARY Burkitt lymphoma (BL) is a disease of predominantly young population, while in the elderly it occurs as a rare neoplasm. Elderly patients (age >60 years) represent a significant problem because of the inability to apply effective aggressive chemiotherapy in these cases. The risk of induction death is very high and unacceptible. Mainly, palliative treatments are applied, whose goal is not curing but maintaining the quality of life. We present the case of a person 75 years old with a diagnosis of sporadic, typical BL treated with CHOP+R in the induction therapy with excellent response but rapid progression after the abolition of rituximab. In discussion, the authors are looking for relevant data on the therapeutic approach in BL in the elderly.

Citation

Copyright

Article metrics